Enzo Biochem, Inc. (NYSE: ENZ) reported Q1 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $25.75 million versus the consensus estimate of $27.04 million.

Earnings